Trends in Launch Prices and Price Increases for Self-Administered Anticancer Drugs in Medicare

Stacie B Dusetzina; Shelley A Jazowski; Rahul K Nayak; Haiden A Huskamp; Nancy L Keating

doi:10.1001/jama.2025.6366

Trends in Launch Prices and Price Increases for Self-Administered Anticancer Drugs in Medicare

JAMA. 2025 Aug 12;334(6):536-538. doi: 10.1001/jama.2025.6366.

Authors

Stacie B Dusetzina^{1

2}, Shelley A Jazowski³, Rahul K Nayak⁴, Haiden A Huskamp⁵, Nancy L Keating^{5

6}

Affiliations

¹ Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee.
² Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
³ Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
⁴ Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia.
⁵ Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
⁶ Brigham and Women's Hospital, Boston, Massachusetts.

No abstract available

Plain language summary

This study examines trends in launch prices and price increases for anticancer therapies covered under Medicare Part D and approved from 2010 to 2024.